Form 8-K

8-K — Vyome Holdings, Inc

Accession: 0001213900-26-093512

Filed: 2026-08-25

Period: 2026-08-25

CIK: 0001427570

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — ea0303228-8k_vyome.htm (Primary)

EX-99.1 — PRESS RELEASE DATED AUGUST 25, 2026 (ea030322801ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0303228-8k_vyome.htm · Sequence: 1

false

0001427570

2026-08-25

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported):

August 25, 2026

VYOME HOLDINGS, INC.

(Exact name of registrant as specified in its

charter)

Delaware

1-37897

26-1828101

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

Harvard Square, One Mifflin Place, Suite 400

Cambridge, MA

02138

(Address of principal executive offices)

(Zip Code)

(949) 429-6680

(Registrant’s telephone number, including

area code)

Not Applicable

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.001 per share

HIND

The Nasdaq Capital Market

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On August 25, 2026, Vyome Holdings, Inc. issued

a press release announcing its financial results for its second fiscal quarter ended June 30, 2026. The full text of the press release

is furnished herewith as Exhibit 99.1.

The information disclosed under this Item 2.02,

including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities

Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be incorporated by reference into any registration statement

or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act except as expressly set forth in such filing.

Item 9.01 Financial Statements and Exhibits

Exhibit No.

Description

99.1

Press Release dated August 25, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VYOME HOLDINGS, INC.

August 25, 2026

By:

/s/ Venkat Nelabhotla

Name:

Venkat Nelabhotla

Title:

President & Chief Executive Officer

EX-99.1 — PRESS RELEASE DATED AUGUST 25, 2026

EX-99.1

Filename: ea030322801ex99-1.htm · Sequence: 2

Exhibit 99.1

Vyome Holdings Reports

Second Quarter 2026 Results Highlighted By Advancement Of Lead

VT-1953 Program, Pipeline Expansion And Strong Balance Sheet

CAMBRIDGE, Mass., August

25, 2026 — Vyome Holdings, Inc. (“Vyome”), a clinical-stage biopharmaceutical company focused on immuno-inflammatory

and rare disease conditions, today reports financial results for the second quarter ended June 30, 2026, and provides a corporate update.

Krishna Gupta, Chairman

of Vyome Holdings, said, “Vyome continues to execute with focus and discipline across its development programs while maintaining

a methodical and conservative approach to capital allocation. During the quarter, we advanced our lead VT-1953 program, broadened our

pipeline through the Impetis agreement and continued to strengthen our intellectual property portfolio. With a strong balance sheet and

disciplined capital structure, we believe Vyome is well positioned to pursue its development priorities and create long-term shareholder

value.”

Venkat Nelabhotla, Vyome

President and Chief Executive Officer, stated, “VT-1953 remains our lead priority. The Phase 2 data presented this year demonstrated

statistically significant improvements in malodor, the patient-reported impact of malodor on daily life, and lesion pain, with no treatment-emergent

adverse events reported. In March 2026, we submitted a pre-IND briefing package to the FDA that included our proposed pivotal clinical

study strategy for the treatment of malodor and other symptoms associated with malignant fungating wounds. During the second quarter of

2026, the Company received the FDA’s written response on the proposed clinical development program. The Company is incorporating

the FDA’s feedback, preparing the appropriate supporting package, and plans to continue its engagement with the FDA through a Type

C meeting to further advance the clinical development program.

“At the same time,

we are selectively building additional opportunities around our core immuno-inflammatory strategy. Our agreement with Impetis adds two

selective JAK inhibitor assets and provides potential access to important autoimmune and inflammatory disease categories. We intend to

advance these opportunities in a disciplined manner with non-dilutive methods while keeping VT-1953 as our primary development focus.

Importantly, we continue to maintain a clean capital structure with no debt, no preferred stock, and no toxic financing instruments. We

believe this combination of focused clinical execution, pipeline optionality, and financial discipline provides a strong foundation for

long-term shareholder value,” concluded Mr. Nelabhotla.

Second Quarter

2026 and Recent Corporate Highlights

● In March 2026, submitted a pre-IND briefing package to the FDA including the proposed pivotal clinical

study strategy for VT-1953; received the FDA’s written response on the proposed clinical development program during the second quarter

is incorporating the FDA’s feedback, preparing the appropriate supporting package, and plans to continue its engagement with the

FDA through a Type C meeting to further advance the clinical development program.

● Presented Phase 2 clinical data on lead candidate VT-1953 topical gel for treatment of malignant fungating

wounds (MFW) at the American Association for Cancer Research (AACR), including:

o Statistically significant reduction in malodor (primary endpoint)

o Statistically significant improvement in patient-reported impact of malodor on daily life

o Statistically significant improvement in lesion pain

o No treatment-emergent adverse events

● Signed agreement with Impetis Biosciences Limited (“Impetis’) to in-license two selective

JAK inhibitor assets designed for higher selectivity to potentially treat autoimmune and inflammatory conditions

● Received a granted Chinese patent covering formulation and therapeutic use claims related to VB-1953 topical

gel program for treating inflammatory acne

Financial Results

for the Quarter Ended June 30, 2026

● Cash and cash equivalents were approximately

$7.9 million as of June 30, 2026, compared with approximately $5.0 million as of December 31, 2025

● Total current assets were approximately $8.2

million as of June 30, 2026

● Total stockholders’ equity was approximately

$7.3 million as of June 30, 2026

● Total operating expenses for the quarter ended

June 30, 2026, were approximately $874,000, including approximately $507,000 in research and development expenses and approximately $365,000

in selling, general, and administrative expenses

● Net loss attributable to common shareholders

for the quarter ended June 30, 2026, was approximately $720,000, or approximately $0.10 per basic and diluted share

Complete financial results

can be found in the Company’s

recent Quarterly Report on Form 10-Q available at sec.gov.

About Vyome Holdings,

Inc.:

Vyome is building the world’s premier platform

spanning the US-India innovation corridor. Vyome’s immediate focus is on leveraging its clinical-stage assets to transform the lives

of patients with immuno-inflammatory conditions. By applying groundbreaking science and its unique positioning, Vyome seeks to deliver

lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety.

To learn more, please visit www.vyometx.com

Forward-Looking Statements

Certain statements made in this press release

are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities

Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “target,” “believe,”

“expect,” “will,” “shall,” “may,” “anticipate,” “estimate,” “would,”

“positioned,” “future,” “forecast,” “intend,” “plan,” “project,”

“outlook”, and other similar expressions that predict or indicate future events or trends or that are not statements of historical

matters. Such statements include, but are not limited to, statements contained in this press release relating to Vyome’s business

strategy, Vyome’s clinical development plans and expected timelines, the expected therapeutic potential of Vyome’s product

candidates and pipeline assets, Vyome’s intellectual property strategy, Vyome’s future operating results, and Vyome’s

liquidity and capital resources outlook. Forward-looking statements are based on Vyome’s current expectations and assumptions regarding

Vyome’s business, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject

to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Vyome’s actual results may differ

materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of

assurance of future performance. Vyome cautions you, therefore, against relying on any of these forward-looking statements. Important

factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation,

Vyome’s ability to raise capital to fund continuing operations; the timing and outcome of Vyome’s interactions with the FDA;

our ability to successfully design, initiate, enroll, and complete clinical trials; our ability to protect Vyome’s intellectual

property rights; the impact of any infringement actions or other litigation brought against Vyome; competition from other providers and

products; Vyome’s ability to develop and commercialize products and services; changes in government regulation; and other factors

relating to Vyome’s industry, operations and results of operations described in the Vyome’s Annual Report on Form 10-K for

the year ended December 31, 2025, our Quarterly Reports on Form 10-Q, our Current Reports on Form 8-K and subsequent filings with the

SEC. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events

that could cause Vyome’s actual results to differ may emerge from time to time, and it is not possible for Vyome to predict all

of them. Vyome cannot guarantee future results, levels of activity, performance, or achievements. Vyome assumes no obligation to update

any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release, except as

may be required under applicable securities law.

Contacts

Media:

ir@vyometx.com

Visit

us on social media:

Facebook

SUMMARY FINANCIAL STATEMENTS

SUMMARY OF CONDENSED CONSOLIDATED BALANCE SHEETS AS OF

June 30,

2026

December 31,

2025

Cash and cash equivalents

$ 7,887,510

$ 4,982,333

Other current assets

265,843

455,988

Long term assets

1,023,009

1,058,856

Total assets

$ 9,176,362

$ 6,497,177

Liabilities

$ 1,864,656

$ 2,735,160

Total Stockholders’ equity (deficit)

7,311,706

3,762,017

Total liabilities and stockholders’ equity

$ 9,176,362

$ 6,497,177

SUMMARY OF CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

Six months

ended

June 30,

2026

Six months

ended

June

30,

2025

Revenues

$ 58,546

$ 248,535

Cost of goods sold

(30,243 )

(69,881 )

Gross profit

28,303

178,654

Operating expenses

2,020,809

701,839

Operating loss

(1,992,506 )

(523,185 )

Interest and other expenses, net

287,302

(79,547 )

Net loss

$ (1,705,204 )

$ (602,732 )

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Aug. 25, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 25, 2026

Entity File Number

1-37897

Entity Registrant Name

VYOME HOLDINGS, INC.

Entity Central Index Key

0001427570

Entity Tax Identification Number

26-1828101

Entity Incorporation, State or Country Code

Entity Address, Address Line One

Harvard Square

Entity Address, Address Line Two

One Mifflin Place

Entity Address, Address Line Three

Suite 400

Entity Address, City or Town

Cambridge

Entity Address, State or Province

Entity Address, Postal Zip Code

02138

City Area Code

949

Local Phone Number

429-6680

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common stock, par value $0.001 per share

Trading Symbol

HIND

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 3 such as an Office Park

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine3

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration